Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Feb 19;321(7):704-706.
doi: 10.1001/jama.2018.19941.

Use of Active Surveillance or Watchful Waiting for Low-Risk Prostate Cancer and Management Trends Across Risk Groups in the United States, 2010-2015

Brandon A Mahal  1 , Santino Butler  1 , Idalid Franco  1 , Daniel E Spratt  2 , Timothy R Rebbeck  1 , Anthony V D'Amico  1 , Paul L Nguyen  1
Affiliations

Use of Active Surveillance or Watchful Waiting for Low-Risk Prostate Cancer and Management Trends Across Risk Groups in the United States, 2010-2015

Brandon A Mahal et al. JAMA. .

Abstract

This cancer epidemiology study uses SEER data to examine US trends in use of active surveillance, watchful waiting, radiotherapy, and surgical management of localized prostate cancer among men with low-, intermediate-, and high-risk disease treated between 2010 and 2015.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Spratt reported serving on an advisory board for Janssen and Blue Earth. Dr Rebbeck reported receipt of grants from the National Institutes of Health. Dr Nguyen reported receipt of consulting fees from Ferring, Augmenix, Bayer, Janssen, Astellas, Dendreon, Genome DX, Blue Earth Diagnostics, Cota, and Nanobiotix; grant funding from Janssen and Astellas; and equity in Augmenix. No other disclosures were reported.

Figures

Figure.
Figure.. Initial Management Trends Among Patients Diagnosed as Having Low-, Intermediate-, and High-Risk Prostate Cancer in the United States From 2010 to 2015 in the Surveillance, Epidemiology, and End Results Prostate Active Surveillance/Watchful Waiting Database
Stratified by National Comprehensive Cancer Network risk category (low risk: n=50 302; intermediate risk: n=81 836; high risk: n=32 622). Error bars indicate 95% confidence intervals.
See this image and copyright information in PMC

Comment in

References

    1. Cooperberg MR, Carroll PR. Trends in management for patients with localized prostate cancer, 1990-2013. JAMA. 2015;314(1):80-82. doi:10.1001/jama.2015.6036 - DOI - PubMed
    1. Klotz L, Vesprini D, Sethukavalan P, et al. . Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. J Clin Oncol. 2015;33(3):272-277. doi:10.1200/JCO.2014.55.1192 - DOI - PubMed
    1. Carroll PH, Mohler JL. NCCN guidelines updates: prostate cancer and prostate cancer early detection. J Natl Compr Canc Netw. 2018;16(5S):620-623. doi:10.6004/jnccn.2018.0036 - DOI - PubMed
    1. Loeb S, Byrne N, Makarov DV, Lepor H, Walter D. Use of conservative management for low-risk prostate cancer in the Veterans Affairs integrated health care system from 2005-2015. JAMA. 2018;319(21):2231-2233. doi:10.1001/jama.2018.5616 - DOI - PMC - PubMed
    1. National Cancer Institute Surveillance, Epidemiology, and End Results Program Prostate With Watchful Waiting database. 2018. https://seer.cancer.gov/seerstat/databases/prostate-ww/index.html. Accessed May 28, 2018.

Substances